Our take
Lifeward sells the ReWalk, the first exoskeleton cleared by the FDA for personal use, along with AlterG anti-gravity treadmills for clinics. Its pricing is unusually visible for medical robotics because Medicare set a lump-sum fee of $91,032 for personal exoskeletons in 2024, and Aetna, Humana, and UnitedHealthcare added Medicare Advantage coverage in 2025.5,2,6
The business is small and in flux. Revenue fell 14% to $22.0 million in 2025, the company lost $19.9 million, and it agreed to a deal that could give Oramed up to 49.99% of its shares. Second-quarter 2026 revenue rose 16% to $6.6 million, and Josh Hexter took over as interim CEO in September 2026.2,3,4
Scores by criterion
Each criterion is defined on our methodology page.
Who uses Lifeward and what it's for
The ReWalk Personal Exoskeleton serves people with spinal cord injury who want to stand and walk at home and in the community, and is often bought through Medicare, the Veterans Health Administration, or private insurers. AlterG systems serve rehabilitation clinics, sports teams, and hospitals.5,2
Lifeward sells directly in the United States and through a mix of direct sales and distributors in Germany, Canada, and Australia.5
ReWalk, AlterG, and ReStore
ReWalk uses tilt sensors, an onboard computer, and motorized legs to let people with paraplegia stand and walk. The FDA cleared stair and curb use in 2023, and ReWalk 7 is the newest model.5,1
Lifeward bought AlterG in August 2023 for about $19 million. AlterG treadmills use NASA-derived differential air pressure to reduce body weight during rehabilitation and are used in more than 4,000 facilities in more than 40 countries. Lifeward also sells the ReStore soft exo-suit for stroke and distributes MYOLYN FES cycles.5
Finances and the Oramed deal
2025 revenue was $22.0 million, down from $25.7 million, with ReWalk sales of $8.5 million. Net loss narrowed to $19.9 million, and the company ended the year with $2.2 million in unrestricted cash.2
Shareholders approved a deal with Oramed Pharmaceuticals under which Lifeward acquires Oramed's oral protein delivery technology and Oramed can own up to 49.99% of Lifeward. Lifeward had $9.4 million in cash at June 30, 2026.2,3
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where Lifeward wins or loses |
|---|---|---|---|---|
| Lifeward | ReWalk personal exoskeleton and AlterG anti-gravity systems2 | Medicare fee of $91,032 for a personal exoskeleton5 | Individual users through Medicare and insurers; AlterG in more than 4,000 facilities5 | Personal use with an established Medicare fee; small, loss-making company |
| Ekso Bionics | EksoNR exoskeleton for gait training after stroke and brain injury7 | Not published7 | Inpatient rehabilitation facilities; first exoskeleton FDA-cleared for stroke7 | Lifeward wins on personal use at home with a Medicare fee. Ekso wins in inpatient rehabilitation for stroke. |
| Wandercraft | Eve self-balancing personal exoskeleton and Atalante X for clinics8,9 | Not published8 | More than 150 clinical centers; acquired Ekso Bionics in 20268,10 | Lifeward wins on a longer record and a Medicare fee. Wandercraft wins on hands-free, self-balancing walking. |
| Myomo | MyoPro powered arm and hand brace16 | Medicare fee schedule rates of $33,481 and $65,87211 | Patients reached through clinician referrals and orthotics and prosthetics channels13,17 | Lifeward wins on walking for people with spinal cord injury. Myomo wins on arm and hand function. |
| Saebo (SaeboFlex) | Non-powered dynamic hand splint with springs that reopen the hand14 | Not published; custom-fit by a trained professional14 | Outpatient clinics and rehabilitation facilities14 | Lifeward wins on powered walking. Saebo wins on low-cost hand rehabilitation. |
Limits
Cash is tight. The company has relied on financing deals and the Oramed transaction to fund operations.2,3
Leadership changed in 2026. Mark Grant left as CEO, Josh Hexter is interim CEO, and Rami Aviram becomes CFO on November 1, 2026.4
The new oral drug delivery business is unrelated to robotics and may pull attention from the core rehabilitation products.2
What customers say
Where it helps
Coverage is the main help for patients. Medicare has a fee schedule for personal exoskeletons, and Medicare Advantage coverage from Aetna, Humana, and UnitedHealthcare reaches about 16 million covered lives, according to Lifeward.5,2
Where it falls short
We found no independent customer reviews. The concerns in public filings are financial: a revenue decline in 2025, continued losses, and dependence on outside financing.2
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation. Based on: Lifeward SEC filings, earnings releases, and website.
Leadership
Josh Hexter
Interim chief executive officerHexter became interim CEO on September 1, 2026. He was previously chief operating and business officer of Oramed Pharmaceuticals and chief business officer of BrainsWay.4
Rami Aviram
Chief financial officerAviram becomes CFO on November 1, 2026, after serving as CFO of Beewise and ENDYMED Medical.4
Sources
- Lifeward, Homepage, accessed November 1, 2026
- Lifeward, Lifeward reports fourth quarter and full year 2025 financial results, March 18, 2026, accessed November 1, 2026
- Lifeward, Lifeward reports strong second quarter 2026 financial results, August 14, 2026, accessed November 1, 2026
- Lifeward, Lifeward appoints Josh Hexter interim chief executive officer, August 31, 2026, accessed November 1, 2026
- Lifeward, Form 10-Q for the quarter ended September 30, 2024, accessed November 1, 2026
- Wikipedia, ReWalk, accessed November 1, 2026
- Ekso Bionics, EksoNR, accessed November 1, 2026
- Wandercraft, Eve personal exoskeleton, accessed November 1, 2026
- Wandercraft, Atalante X, accessed November 1, 2026
- Wandercraft, Wandercraft acquires Ekso Bionics, accessed November 1, 2026
- Myomo, CMS posts final Medicare DMEPOS fee schedule rate for the MyoPro, March 1, 2024, accessed October 31, 2026
- Myomo, About Myomo, accessed November 1, 2026
- Myomo, Second quarter 2026 results, SEC exhibit 99.1, August 5, 2026, accessed October 31, 2026
- Saebo, SaeboFlex, accessed November 1, 2026
- Saebo, Home page, accessed November 1, 2026
- Myomo, Homepage, accessed October 31, 2026
- Myomo, Fourth quarter and full year 2025 results, accessed October 31, 2026
